Speaker Profile

Ph.D., CEO and Co-founder, ImpriMed

Biography
Sungwon Lim is a bioengineer/entrepreneur with 20 years of collective experience in academia, pharmaceutical companies, and biotech industries. He co-founded ImpriMed in 2017 with a strong motivation to innovate a way to help cancer patients who need an effective treatment ‘today, by optimizing and personalizing drug treatment options currently available in our medical toolbox. ImpriMed builds a comparative oncology platform for precision medicine. The team first develops and validates new cell-based, functional precision medicine technologies and AI-based predictive models in the veterinary oncology space at a significantly higher speed with readily accessible clinical data. Then the collected database and knowledge are applied to human oncology for the same cancer type. Dr. Lim received his Ph.D. in Bioengineering from Stanford University, M.S. in Translational Medicine at U.C. Berkeley and U.C. San Francisco, and B.S. in Chemical and Biomolecular Engineering at Korea Advanced Institute of Science and Technology.


Clinical Dx Showcase:
ImpriMed

ImpriMed provides an anticancer drug efficacy prediction service using artificial intelligence on a patient's live cancer cell data, aiming to help oncologists personalize a treatment regimen tailored to each patient's unique cancer in both human and veterinary oncology.

Reinventing precision medicine: from dogs to humans
ImpriMed’s comparative oncology platform enables new precision medicine services for both human and animal cancers.

 Session Abstract – PMWC 2023 Silicon Valley

Showcase Track S2 - January 25 9.00 A.M.-1.15 P.M.,Showcase Track S2 - January 26 9.00 A.M.-1.15 P.M.,Showcase Track S1 - January 27 11.15 A.M.-3.00 P.M.


The PMWC 2023 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

  • Clinical Dx/Oncology (including Liquid Biopsy)
  • Clinical Dx/Cardio Vascular
  • Clinical Dx/Nerodegenerative